EBITDA: Income before interest, taxes, depreciation and amortization.
Edgewise Therapeutics, Inc. (EWTX) had EBITDA of $-47.33M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-40.80M |
|
-- |
|
-- |
|
$45.96M |
|
$-45.96M |
|
$5.16M |
|
$-40.80M |
|
$-40.80M |
|
$-40.80M |
|
$-40.80M |
|
$-40.80M |
|
$-40.80M |
|
$-45.96M |
|
|
EBITDA |
$-47.33M |
95.13M |
|
95.13M |
|
$-0.43 |
|
$-0.43 |
|
| Balance Sheet Financials | |
$443.18M |
|
$8.99M |
|
$11.21M |
|
$454.39M |
|
$21.11M |
|
-- |
|
$3.56M |
|
$24.67M |
|
$429.72M |
|
$429.72M |
|
$429.72M |
|
95.21M |
|
| Cash Flow Statement Financials | |
$-37.87M |
|
$43.90M |
|
$2.22M |
|
$41.67M |
|
$49.92M |
|
$8.26M |
|
$9.06M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
20.99 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-37.91M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.49% |
|
-9.49% |
|
-8.98% |
|
-9.49% |
|
$4.51 |
|
$-0.40 |
|
$-0.40 |
|